CNS Pharmaceuticals, Inc.
CNSP
$6.12
-$0.42-6.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.24M | 1.09M | 1.70M | 1.38M | 1.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.41M | 4.34M | 3.20M | 5.63M | 2.53M |
| Operating Income | -2.41M | -4.34M | -3.20M | -5.63M | -2.53M |
| Income Before Tax | -2.38M | -4.30M | -3.18M | -5.61M | -2.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.38M | -4.30M | -3.18M | -5.61M | -2.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.38M | -4.30M | -3.18M | -5.61M | -2.53M |
| EBIT | -2.41M | -4.34M | -3.20M | -5.63M | -2.53M |
| EBITDA | -2.41M | -4.34M | -3.20M | -5.63M | -2.53M |
| EPS Basic | -6.42 | -18.93 | -35.49 | -151.64 | -- |
| Normalized Basic EPS | -4.01 | -11.83 | -22.18 | -94.78 | -- |
| EPS Diluted | -6.42 | -18.96 | -35.55 | -151.64 | -- |
| Normalized Diluted EPS | -4.01 | -11.83 | -22.18 | -94.78 | -- |
| Average Basic Shares Outstanding | 370.10K | 227.20K | 89.50K | 37.00K | -- |
| Average Diluted Shares Outstanding | 370.10K | 227.20K | 89.50K | 37.00K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |